Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by MERRILL S KIES and ADAM S GARDEN.
MERRILL S KIES
Connection Strength
2.186
ADAM S GARDEN
  1. Reply to radiotherapy for human papillomavirus-positive oropharyngeal cancers in the National Cancer Data Base. Cancer. 2016 11 15; 122(21):3411-3412.
    View in: PubMed
    Score: 0.140
  2. Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer. Cancer. 2016 06 01; 122(11):1702-7.
    View in: PubMed
    Score: 0.137
  3. Depression and Oropharynx Cancer Outcome. Psychosom Med. 2016 Jan; 78(1):38-48.
    View in: PubMed
    Score: 0.135
  4. Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer. Head Neck. 2016 04; 38 Suppl 1:E1554-61.
    View in: PubMed
    Score: 0.134
  5. Long-term functional and survival outcomes after induction chemotherapy and risk-based definitive therapy for locally advanced squamous cell carcinoma of the head and neck. Head Neck. 2014 Apr; 36(4):474-80.
    View in: PubMed
    Score: 0.113
  6. Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. Radiat Oncol. 2013 Jan 29; 8:21.
    View in: PubMed
    Score: 0.110
  7. To TORS or Not to TORS: but is that the question? Comment on "transoral robotic surgery for advanced oropharyngeal carcinoma". Arch Otolaryngol Head Neck Surg. 2010 Nov; 136(11):1085-7.
    View in: PubMed
    Score: 0.094
  8. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2010 Jan 01; 28(1):8-14.
    View in: PubMed
    Score: 0.088
  9. Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009 Nov 01; 75(3):725-33.
    View in: PubMed
    Score: 0.085
  10. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys. 2009 Feb 01; 73(2):399-409.
    View in: PubMed
    Score: 0.080
  11. Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2008 Nov 01; 72(3):747-55.
    View in: PubMed
    Score: 0.079
  12. Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer. 2004 Dec 01; 101(11):2567-73.
    View in: PubMed
    Score: 0.063
  13. Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma. Clin Cancer Res. 2024 Nov 12.
    View in: PubMed
    Score: 0.062
  14. Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma? Cancer. 2004 Mar 15; 100(6):1171-8.
    View in: PubMed
    Score: 0.060
  15. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2019 03 01; 30(3):471-477.
    View in: PubMed
    Score: 0.042
  16. Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. Semin Radiat Oncol. 2018 04; 28(2):108-113.
    View in: PubMed
    Score: 0.039
  17. Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. Head Neck. 2017 08; 39(8):1609-1620.
    View in: PubMed
    Score: 0.037
  18. Delayed lower cranial neuropathy after oropharyngeal intensity-modulated radiotherapy: A cohort analysis and literature review. Head Neck. 2017 08; 39(8):1516-1523.
    View in: PubMed
    Score: 0.037
  19. Long-term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches. Head Neck. 2016 12; 38(12):1739-1751.
    View in: PubMed
    Score: 0.035
  20. Predicting two-year longitudinal MD Anderson Dysphagia Inventory outcomes after intensity modulated radiotherapy for locoregionally advanced oropharyngeal carcinoma. Laryngoscope. 2017 04; 127(4):842-848.
    View in: PubMed
    Score: 0.035
  21. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis. Radiother Oncol. 2016 07; 120(1):48-55.
    View in: PubMed
    Score: 0.035
  22. Long-Term, Prospective Performance of the MD?Anderson Dysphagia Inventory in "Low-Intermediate Risk" Oropharyngeal Carcinoma After Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017 03 15; 97(4):700-708.
    View in: PubMed
    Score: 0.035
  23. Postoperative Intensity-Modulated Proton Therapy for Head and Neck Adenoid Cystic Carcinoma. Int J Part Ther. 2016 Mar; 2(4):533-543.
    View in: PubMed
    Score: 0.034
  24. Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1117-31.
    View in: PubMed
    Score: 0.034
  25. Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):360-367.
    View in: PubMed
    Score: 0.034
  26. Definitive proton radiation therapy and concurrent cisplatin for unresectable head and neck adenoid cystic carcinoma: A series of 9 cases and a critical review of the literature. Head Neck. 2016 04; 38 Suppl 1:E1472-80.
    View in: PubMed
    Score: 0.033
  27. Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation. Int J Cancer. 2016 Mar 01; 138(5):1290-7.
    View in: PubMed
    Score: 0.033
  28. A Multidisciplinary Orbit-Sparing Treatment Approach That Includes Proton Therapy for Epithelial Tumors of the Orbit and Ocular Adnexa. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):344-352.
    View in: PubMed
    Score: 0.033
  29. Merkel cell carcinoma of the head and neck: Favorable outcomes with radiotherapy. Head Neck. 2016 04; 38 Suppl 1:E452-8.
    View in: PubMed
    Score: 0.033
  30. Long-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3-decade survey. Cancer. 2015 May 15; 121(10):1608-19.
    View in: PubMed
    Score: 0.032
  31. Multifield optimization intensity modulated proton therapy for head and neck tumors: a translation to practice. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):846-53.
    View in: PubMed
    Score: 0.030
  32. Prognostic factors associated with decreased survival in patients with acinic cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2013 Nov; 139(11):1195-202.
    View in: PubMed
    Score: 0.029
  33. Prognostic factors in mucoepidermoid carcinoma of the salivary glands. Cancer. 2012 Aug 15; 118(16):3928-36.
    View in: PubMed
    Score: 0.025
  34. Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2010 Dec 01; 78(5):1356-65.
    View in: PubMed
    Score: 0.023
  35. Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol. 2009 Apr 20; 27(12):1976-82.
    View in: PubMed
    Score: 0.021
  36. The M. D. Anderson symptom inventory-head and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis. Int J Radiat Oncol Biol Phys. 2008 Dec 01; 72(5):1355-61.
    View in: PubMed
    Score: 0.020
  37. Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck. 2007 Oct; 29(10):923-31.
    View in: PubMed
    Score: 0.019
  38. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2006 Sep 01; 24(25):4163-9.
    View in: PubMed
    Score: 0.018
  39. Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management. Head Neck. 2004 Sep; 26(9):796-807.
    View in: PubMed
    Score: 0.015
  40. A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status. Cancer. 2004 Mar 01; 100(5):991-8.
    View in: PubMed
    Score: 0.015
  41. Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. Cancer. 2003 Nov 15; 98(10):2214-23.
    View in: PubMed
    Score: 0.015
  42. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer. 2002 Jul 15; 95(2):322-30.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.